ARTICLE | Management Tracks
Incoming Sanofi CEO Garijo will need to hunt for growth drivers
Pharma’s board dismisses Paul Hudson as it faces Dupixent cliff in early 2030s
February 12, 2026 10:59 PM UTC
Incoming Sanofi CEO Belén Garijo will inherit the challenge of finding growth drivers to offset Dupixent’s upcoming patent cliff when she takes the role from Paul Hudson this spring.
Sanofi (Euronext:SAN; NASDAQ:SNY) said early Thursday that its board “decided not to renew the Director mandate” of Hudson, spelling an end to his tenure on Tuesday, Feb. 17. EVP of General Medicines Olivier Charmeil will be interim CEO until Garijo arrives on April 29...